Pharming (PHAR) Share-based Compensation (2020 - 2025)
Pharming's (PHAR) quarterly Share-based Compensation came in at $4.5 million in Q4 2025, up 70.64% YoY from $2.6 million in Q4 2024, and up 70.64% on a QoQ basis from $2.6 million in Q4 2024.
Pharming (PHAR) Share-based Compensation (2020 - 2025) Analysis & Trends
Pharming (PHAR) has 6 years of Share-based Compensation data on file, last reported at $4.5 million in Q4 2025.
- Quarterly Share-based Compensation rose 70.64% year-over-year to $4.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.4 million (up 23.47% YoY) and the FY2025 annual result came in at $13.8 million, up 22.39% from the prior year.
- Share-based Compensation advanced to $4.5 million in Q4 2025, from $2.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.5 million in Q4 2025 to a low of -$3.7 million in Q3 2021.
- A 5-year average of $1.8 million and a median of $2.0 million in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 27886.73% in 2021, down 548.57% in 2021.
- Tracing PHAR's Share-based Compensation over 5 years: stood at $1.9 million in 2021, then slumped by 43.95% to $1.1 million in 2022, then surged by 209.91% to $3.3 million in 2023, then decreased by 20.3% to $2.6 million in 2024, then soared by 70.64% to $4.5 million in 2025.
- The last three Share-based Compensation figures came in at $4.5 million (Q4 2025), $2.6 million (Q4 2024), and $2.9 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.51 Mn |
| Dec 31, 2025 | 4.51 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Dec 31, 2023 | 3.32 Mn |
| Dec 31, 2023 | 3.32 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Dec 31, 2021 | 1.91 Mn |
| Dec 31, 2021 | 1.91 Mn |
| Sep 30, 2021 | -3.70 Mn |
| Sep 30, 2021 | -3.70 Mn |
| Dec 31, 2020 | 6,821.09 |
| Dec 31, 2020 | 6,821.09 |